NR1H4 and metabolic dysfunction-associated steatotic liver disease: Some synthetic farnesoid X receptor (FXR) agonists, including GW4064 [21], obeticholic acid [19] and INT-747 [22], could increase hepatic DDAH1 expression and attenuate the development of NAFLD.